X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (27) 27
humans (25) 25
oncology (23) 23
female (19) 19
middle aged (17) 17
mutation (17) 17
adult (13) 13
brca1 (11) 11
further section · weitere sektionen (11) 11
genetic aspects (11) 11
aged (10) 10
cancer (10) 10
breast cancer (9) 9
tumors (9) 9
chemotherapy (8) 8
male (8) 8
medicine & public health (8) 8
analysis (7) 7
brca1 protein - genetics (7) 7
breast neoplasms - genetics (7) 7
genetic predisposition to disease (7) 7
loss of heterozygosity (7) 7
lung cancer (7) 7
lung neoplasms - genetics (7) 7
neoadjuvant therapy (7) 7
gefitinib (6) 6
gene mutations (6) 6
germ-line mutation (6) 6
lung neoplasms - drug therapy (6) 6
neoplasm staging (6) 6
adenocarcinoma - genetics (5) 5
adenocarcinoma - pathology (5) 5
antineoplastic agents - therapeutic use (5) 5
breast neoplasms - pathology (5) 5
egfr (5) 5
health aspects (5) 5
internal medicine (5) 5
mutation - genetics (5) 5
pathology (5) 5
receptor, epidermal growth factor - genetics (5) 5
russia (5) 5
adenocarcinoma - drug therapy (4) 4
base sequence (4) 4
breast-cancer (4) 4
cancer patients (4) 4
care and treatment (4) 4
colorectal cancer (4) 4
dna mutational analysis (4) 4
gene (4) 4
hematology (4) 4
hematology, oncology and palliative medicine (4) 4
lung neoplasms - pathology (4) 4
ovarian cancer (4) 4
ovarian neoplasms - drug therapy (4) 4
prognosis (4) 4
risk (4) 4
risk factors (4) 4
studies (4) 4
treatment outcome (4) 4
activation (3) 3
adjuvant treatment (3) 3
aged, 80 and over (3) 3
biomarkers, tumor - genetics (3) 3
braf (3) 3
breast (3) 3
cancer therapies (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
carcinoma, non-small-cell lung - genetics (3) 3
contents · inhalt (3) 3
erlotinib (3) 3
founder mutations (3) 3
genes (3) 3
genes, brca1 (3) 3
genetic research (3) 3
genetic testing (3) 3
hereditary cancer syndromes (3) 3
high-frequency (3) 3
inhibitors (3) 3
microsatellite instability (3) 3
ovarian neoplasms - genetics (3) 3
polymorphism, single nucleotide (3) 3
primary surgery (3) 3
protein kinase inhibitors - therapeutic use (3) 3
proto-oncogene proteins b-raf - genetics (3) 3
quinazolines - therapeutic use (3) 3
receptor, epidermal growth factor - antagonists & inhibitors (3) 3
research (3) 3
resistance (3) 3
review (3) 3
surgery (3) 3
therapy (3) 3
young adult (3) 3
1st-line gefitinib (2) 2
activating mutations (2) 2
adenocarcinoma (2) 2
anaplastic lymphoma kinase (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
biochemistry & molecular biology (2) 2
blm (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Cancer, ISSN 0020-7136, 05/2014, Volume 134, Issue 10, pp. 2352 - 2358
Journal Article
Investigational new drugs, ISSN 0167-6997, 08/2019, pp. 1 - 5
Colorectal carcinomas (CRCs) caused by hereditary biallelic MUTYH gene mutations are characterized by elevated mutation load and high lymphocyte infiltration.... 
Microsatellites | Stability | Invasiveness | Colorectal carcinoma | Colorectal cancer | Microsatellite instability | Metastases | Chemotherapy | Immune checkpoint | Lymphocytes | Infiltration | Mutation | Tumors | Cancer
Journal Article
Cancer Cytopathology, ISSN 1934-662X, 07/2013, Volume 121, Issue 7, pp. 370 - 376
Journal Article
Cancer Letters, ISSN 0304-3835, 2015, Volume 362, Issue 1, pp. 116 - 121
Journal Article
European journal of medical genetics, ISSN 1769-7212, 09/2019, p. 103753
Hereditary non-polyposis colorectal cancer (HNPCC), also known as Lynch syndrome (LS), is a common cancer-predisposing syndrome. This study aimed to... 
Journal Article
Journal Article
Cancer Letters, ISSN 0304-3835, 2017, Volume 397, pp. 127 - 132
Abstract Ovarian carcinomas (OC) often demonstrate rapid tumor shrinkage upon neoadjuvant chemotherapy (NACT). However, complete pathologic responses are very... 
Hematology, Oncology and Palliative Medicine | Neoadjuvant therapy | Loss-of-heterozygosity | Treatment resistance | BRCA1 | Ovarian cancer | PROTEIN | SECONDARY MUTATIONS | FOUNDER MUTATIONS | CHEMOTHERAPY | BREAST | PRIMARY SURGERY | ONCOLOGY | RESISTANCE | Adenocarcinoma - pathology | Humans | Ovarian Neoplasms - pathology | Loss of Heterozygosity | Neoplasm, Residual | Neoplasms, Cystic, Mucinous, and Serous - genetics | Ovarian Neoplasms - genetics | Germ-Line Mutation | Female | Neoadjuvant Therapy | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Adenocarcinoma - genetics | Chemotherapy, Adjuvant | Ovarian Neoplasms - drug therapy | Genetic Predisposition to Disease | Neoplasms, Cystic, Mucinous, and Serous - pathology | Neoplasm Recurrence, Local | Treatment Outcome | Adenocarcinoma - drug therapy | BRCA1 Protein - genetics | Drug Resistance, Neoplasm - genetics | Phenotype | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Polymorphism, Single Nucleotide | Medical research | Care and treatment | Gene mutations | Adjuvant treatment | Medicine, Experimental | Genetic aspects | Single nucleotide polymorphisms | Chromosomes | Health aspects | Cancer | Genes | Cloning | Shrinkage | Nucleotides | Patients | Cancer therapies | Proteins | Carriers | Chemotherapy | Reversion | Restoration | Surgery | Genetic testing | Mutation | Deoxyribonucleic acid--DNA | Tumors | Polymorphism
Journal Article
Medical Oncology, ISSN 1357-0560, 6/2013, Volume 30, Issue 2, pp. 1 - 9
Sensitivity of gastric cancer (GC) to conventional cytotoxic therapy may be at least in part attributed to molecular features of the tumor cells. We analyzed... 
Pathology | Medicine & Public Health | Hematology | Hereditary cancer syndromes | Loss of heterozygosity | Oncology | Internal Medicine | Predictive markers | BRCA1 | Gastric cancer | Cytotoxic therapy | MUTATION CARRIERS | OVARIAN-CANCER | FOUNDER MUTATIONS | TUMORS | BREAST-CANCER | GENE | ONCOLOGY | PROTEIN EXPRESSION | HIGH-FREQUENCY | Genetic aspects | RNA | Stomach cancer | Analysis | Cancer
Journal Article
Journal Article
Chinese Clinical Oncology, ISSN 2304-3865, 12/2018, Volume 7, Issue 6
Journal Article